logo
Weather page
GET THE APP
ePaper
google_play
app_store
  • Login
  • E-Edition
  • Sports
  • Obits
  • News
  • Opinion
  • Classifieds
    • Place an Ad
    • All Listings
    • Jobs
  • SPECIAL SECTIONS
  • GALLERY
  • CONTESTS
  • LIFESTYLE/ENTERTAINMENT
  • GAMES
  • Allegany County Source
    • News
      • local
      • state
      • nation/world
    • Sports
      • local
      • college
      • State
      • national
    • obits
    • Opinion
      • News
        • local
        • state
        • nation/world
      • Sports
        • local
        • college
        • State
        • national
      • obits
      • Opinion
    logo
    • Classifieds
      • Place an Ad
      • All Listings
      • Jobs
    • E-Edition
    • Subscribe
    • Login
      • Classifieds
        • Place an Ad
        • All Listings
        • Jobs
      • E-Edition
      • Subscribe
      • Login
    Home

    Olean Times Herald

    Posts
    Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia
    Press Releases
    Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia
    Vanda Pharmaceuticals Inc. 
    March 31, 2025
    WASHINGTON , March 31, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a New Drug Application (NDA) was su...
    Read More...
    {"website":"Website"}
    Vanda Pharmaceuticals announces the publication of an article titled “Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S”
    Press Releases
    Vanda Pharmaceuticals announces the publication of an article titled “Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S”
    Vanda Pharmaceuticals Inc. 
    February 24, 2025
    WASHINGTON , Feb. 24, 2025 /PRNewswire/ --Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of an article entitled "Po...
    Read More...
    {"website":"Website"}
    Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
    Press Releases
    Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
    Vanda Pharmaceuticals Inc. 
    February 13, 2025
    WASHINGTON , Feb.13, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the ...
    Read More...
    {"website":"Website"}
    Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025
    Press Releases
    Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025
    Vanda Pharmaceuticals Inc. 
    February 5, 2025
    Conference Call and Webcast to Follow WASHINGTON , Feb. 5, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it w...
    Read More...
    {"website":"Website"}
    Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis
    Press Releases
    Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis
    Vanda Pharmaceuticals Inc. 
    January 27, 2025
    WASHINGTON , Jan. 27, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant development p...
    Read More...
    {"website":"Website"}
    Vanda’s Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review
    Press Releases
    Vanda’s Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review
    Vanda Pharmaceuticals Inc. 
    January 8, 2025
    WASHINGTON , Jan. 8, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) letter to FDA Commissioner highlights faulty gastroparesis...
    Read More...
    {"website":"Website"}
    Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera
    Press Releases
    Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera
    Vanda Pharmaceuticals Inc. 
    December 20, 2024
    WASHINGTON , Dec. 20, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FD...
    Read More...
    {"website":"Website"}
    Local & Social

    Get in touch with Olean Times Herald

    Submit Content
    Send a Letter to the Editor Place Wedding Announcement Place Engagement Announcement
    Advertise
    Place Birth Announcement Place Anniversary Announcement Place Obituary
    Subscribe
    Start a Subscription e-Edition Contact Us
    Illinois Hancock Journal-Pilot Iroquois Times-Republic Journal-Republican The News-Gazette
    Indiana Fountain Co. Neighbor Herald Journal KV Post News Newton Co. Enterprise Rensselaer Republican Review-Republican
    Iowa Atlantic News Telegraph Audubon Advocate-Journal Barr's Post Card News Burlington Hawk Eye Collector's Journal Fayette County Union Ft. Madison Daily Democrat Independence Bulletin-Journal Keokuk Daily Gate City Oelwein Daily Register Vinton Newspapers Waverly Newspapers
    Michigan Iosco County News-Herald Ludington Daily News Oceana's Herald-Journal Oscoda Press White Lake Beacon New York Finger Lakes Times Olean Times Herald Salamanca Press
    Pennsylvania Bradford Era Clearfield Progress Courier Express Free Press Courier Jeffersonian Democrat Leader Vindicator Potter Leader-Enterprise The Wellsboro Gazette
    © Copyright Olean Times Herald 639 Norton Drive, Olean, NY 14760  | Terms of Use  | Privacy Policy
    Powered by TECNAVIA